Epilepsy Drugs Market: Rapidly Evolving Industry…… COVID-19….
The global epilepsy
drugs market is expected to
reach over USD 5,474.14 million by 2024,
according to a new report by Grand View Research, Inc. The rising government
funding for the development of new and effective drugs for the treatment of
seizures is a high impact rendering driver for the epilepsy drugs market
growth. The American Epilepsy Society (AES) in alliance with other
organizations, such as American Academy of Neurology, the Epilepsy Foundation,
and the Grass Foundation, provide funding for R&D activities and offer
treatment line awareness trainingto the physicians through different programs.
Multiple therapeutic regimens are being
followed across the globe in attempts to come up with a reliable treatment for
Covid-19. One line of treatment includes the use of hydroxychloroquine, while a
second treatment line focuses to use antiviral drugs used in the disease
management of HIV. Both these approaches have surged demand from advanced
antivirals and antimalarial drugs. This impacts the drug manufacturers as an
off label indication for these drug classes has to be worked upon. At the
moment, the WHO has not prescribed any of these approaches, neither they have
commented if one is better than the other. The report will account for Covid19
as a key market contributor.
Furthermore, various awareness
programs conducted by organizations, such as the Epilepsy Foundation, the
American Epilepsy Society, Epilepsy Association of Central Florida, CURE
Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis
and treatment rates. This is expected to propel the market growth over the
forecast period.
Some of the key players of the epilepsy drugs
market are UCB Pharma Ltd., Sanofi S.A, Valeant Pharmaceuticals International,
Inc., Pfizer, Inc., Johnson & Johnson, Eisai Co., Ltd., Abbott
Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC., Sunovion
Pharmaceuticals, Inc., and Cephalon, Inc.
To Request Sample Copy of this report, click the link:
Further key findings from the study suggest:
·
The second generation
anti-epileptic drug class is estimated to have over 30% market share in 2015
owing to the high prescription rates, improved tolerability, and increased
efficacy due to the novel mechanisms of action of these drugs
·
The third generation
anti-epileptic drug class is expected to witness the fastest growth with a CAGR
of over 4% over the forecast period. The major factors responsible for the
growth of this segment include the launch of high efficacy drugs with improved
mechanism of action and fewer side effects, and the awaited launch of new
pipeline drugs.
·
The growing need to improve the
efficacy of the existent drugs and the need to develop new and enhanced
anti-epileptic drugs to minimize the associated side-effects, such as
dizziness, fatigue, weight gain, and depression are the propelling factors
expected to drive the market growth over the forecast period
·
North America dominated the
market in terms of revenue with over USD 2,000 million in 2015 owing to the
presence of well-established healthcare infrastructure, favorable government
initiatives directed at the betterment of the healthcare system, and the
presence of extensive research and development activities
·
Asia Pacific is expected to
witness lucrative growth with a CAGR of around 4.5% over the forecast period
owing to the rising disposable income levels and the favorable, healthcare
government initiatives in emerging economies, such as India, Japan, and China
·
Some major players of the
epilepsy drugs market include UCB Pharma Ltd., Sanofi S.A, Valeant
Pharmaceuticals International, Inc., Pfizer, Inc., Johnson & Johnson, Eisai
Co., Ltd., Abbott Laboratories, Inc., Novartis AG, GlaxoSmithKline PLC.,
Sunovion Pharmaceuticals, Inc., and Cephalon, Inc.
·
Most of the key players are
engaged in strengthening their product portfolio to increase their market
share. The introduction of novel drugs is expected to foster the market
penetration of anti-epileptic drugs. For instance, in August 2015, the
FDA-approved epilepsy tablet, Aptiomby Sunovion Pharmaceuticals, Inc. for
people suffering from partial-onset seizures.
The global epilepsy drugs market was valued at USD 4,100 million
in 2015. The expected launch of drugs currently in the pipeline, such as
Ganaxolone by Marinus Pharmaceuticals, Inc., Perampanel by Eisai Co., Ltd.,
USL261 by Upsher Smith Laboratories, Inc., and YKP3089 by SK Life Sciences,
Inc. is a high impact rendering driver of the epilepsy drugs market.
VX765 by Vertex Pharmaceuticals, Inc. and YKP3089 by SK Life
Sciences, Inc. are some of the Phase IIb drugs. Phase III clinical trials
include NRL-1 intranasal Diazepam, Carbamazepine IV, Diazepam Auto-injector
(Vanquix), and Topiramate Extended-Release (USL-255). In December 2015, NRL-1
by Neurelis, Inc. received the FDA’s Orphan Drug Designation for treating acute
repetitive seizures.
In 2013, 4.3 million adults and 750,000 children of 0-17 years
were diagnosed with epilepsy. The rising prevalence of epilepsy and the
increasing demand for third-generation anti-epileptic drugs, such as Zebinix,
Sunovion, Stedesa, Trobalt, and Potig, are expected to fuel the epileptic drug
market growth over the forecast period.
The rising awareness levels about epilepsy coupled with
strategic alliances are anticipated to stimulate the market growth. The
awareness initiatives by epilepsy networks have led to an increase in demand
for better diagnosis and effective treatment of the disease. For instance, in
2009, the Epilepsy Association of Nova Scotia and the Anita Kaufmann Foundation
together announced March 26 as the “Purple Day” internationally to increase the
worldwide awareness about epilepsy.
The
epilepsy drugs market consists of first generation drugs, second generation
drugs, and third generation drugs. The first generation drug class includes
phenobarbital, Carbamazepine (Tegretol), Valproate (Depakote), Ethosuximide
(Zarontin), and Primidone (Mysoline). Carbamazepine (Tegretol) is the most
commonly prescribed drug for the treatment of generalized and partial seizures.
Have any Query? Ask our Experts:
Grand View Research has segmented the global epilepsy
drugs market on the basis of treatment:
Global Epilepsy Drug market (Revenue, USD Million,
2013 - 2024)
·
First generation anti-epileptic drug
·
Second generation anti-epileptic drug
·
Third generation anti-epileptic drug
The second generation anti-epileptic drug class includes
Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and
Perampanel (Fycompa). The second generation drug class dominated the market in
2015 owing to its high tolerability and safety due to the launch of highly
potent drugs, which employ novel mechanisms of action. In February 2016, the
FDA approved the Briviact, which is used to treat the partial onset of seizures
in people aged 16 years and above.
The third generation drug class is expected to witness the
fastest growth of over 4% over the forecast period owing to the rising
penetration and the increasing adoption of these drugs, such as Lacosamide,
Retigabine, and Eslicarbazepine.
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
Comments
Post a Comment